Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 2, 2016, Pages 285-294

  El Khoury, Petra ^a,b   Waldmann, Elisa ^d   Huby, Thierry ^a,c   Gall, Julie ^a   Couvert, Philippe ^a,c   Lacorte, Jean Marc ^a,c   Chapman, John ^e   Frisdal, Eric ^a,c   Lesnik, Philippe ^a,c   Parhofer, Klaus G ^d   Le Goff, Wilfried ^a,c   Guerin, Maryse ^a,c  

^a SORBONNE UNIVERSITÉ   (France)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF MUNICH   (Germany)

^e INSERM   (France)

Author keywords

CETP; cholesterol efflux; HDL CE uptake; in vivo metabolic studies; macrophage

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; CHOLESTEROL; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MK-0524; NICOTINIC ACID;

ADULT; ANIMAL CELL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; DRUG EFFICACY; DYSLIPIDEMIA; FECES; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; LIVER CELL; MACROPHAGE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PHENOTYPE; POSTPRANDIAL STATE; PRIORITY JOURNAL; AGED; ANIMAL; BLOOD; CHEMISTRY; CHO CELL LINE; CLINICAL TRIAL; CRICETULUS; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; GENETIC TRANSFECTION; GENETICS; LIVER; METABOLISM; TIME FACTOR; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHO CELLS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CRICETULUS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FECES; FEMALE; HUMANS; INDOLES; LIVER; MACROPHAGES; MALE; MICE, TRANSGENIC; MIDDLE AGED; NIACIN; POSTPRANDIAL PERIOD; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84955662453     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306834     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014 129 e28 e292. doi: 10.1161/01.cir.0000441139.02102.80.
2. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005 45 185 197. doi: 10.1016/j.jacc.2004.10.031.
3. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 365 2255 2267
4. Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL, AIM-HIGH Investigators Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 2014 371 288 290. doi: 10.1056/NEJMc1311039.
5. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014 371 203 212
6. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000
7. Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 367 2089 2099. doi: 10.1056/NEJMoa1206797.
8. Voight BF, Peloso GM, Orho-Melander M, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012 380 572 580. doi: 10.1016/S0140-6736(12)60312-2.
9. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010 30 1430 1438. doi: 10.1161/ATVBAHA.110.207142.
10. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011 364 127 135. doi: 10.1056/NEJMoa1001689.
11. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL, Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013 33 1696 1705. doi: 10.1161/ATVBAHA.113.301373.
12. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ, Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 2002 43 1652 1660
13. Tall A, Granot E, Brocia R, Tabas I, Hesler C, Williams K, Denke M, Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest 1987 79 1217 1225. doi: 10.1172/JCI112940.
14. Riemens SC, Van Tol A, Sluiter WJ, Dullaart RP, Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J Lipid Res 1999 40 1459 1466
15. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr, Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983 80 1449 1453
16. Bellanger N, Julia Z, Villard EF, El Khoury P, Duchene E, Chapman MJ, Fournier N, Le Goff W, Guerin M, Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012 221 160 168. doi: 10.1016/j.atherosclerosis.2011.12.027.
17. Guérin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ, Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001 21 282 288
18. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004 20 1253 1268. doi: 10.1185/030079904125004402.
19. Usman MH, Qamar A, Gadi R, Lilly S, Goel H, Hampson J, Mucksavage ML, Nathanson GA, Rader DJ, Dunbar RL, Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med 2012 125 1026 1035. doi: 10.1016/j.amjmed.2012.03.017.
20. Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB, Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. Vasc Health Risk Manag 2014 10 279 290. doi: 10.2147/VHRM.S58694.
21. Blackburn P, Côté M, Lamarche B, Couillard C, Pascot A, Tremblay A, Bergeron J, Lemieux I, Després JP, Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size. Metabolism 2003 52 1379 1386
22. Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ, Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2008 28 148 154. doi: 10.1161/ATVBAHA.107.151688.
23. Lassel TS, Guerin M, Auboiron S, Guy-Grand B, Chapman MJ, Evidence for a cholesteryl ester donor activity of LDL particles during alimentary lipemia in normolipidemic subjects. Atherosclerosis 1999 147 41 48
24. Lassel TS, Guérin M, Auboiron S, Chapman MJ, Guy-Grand B, Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol 1998 18 65 74
25. Lottenberg SA, Lottenberg AM, Nunes VS, McPherson R, Quintão EC, Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in Type II diabetics and normal controls. Atherosclerosis 1996 127 81 90
26. Fujioka Y, Ishikawa Y, Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009 16 145 154
27. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS, Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 2005 7 140 147
28. Kashyap ML, Srivastava LS, Chen CY, Perisutti CG, Campbell M, Lutmer RF, Glueck CJ, Radioimmunoassay of human apolipoprotein CII. A study in normal and hypertriglyceridemic subjects. J Clin Invest 1977 60 171 180. doi: 10.1172/JCI108753.
29. van der Hoorn JW, de Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HM, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008 28 2016 2022. doi: 10.1161/ATVBAHA.108.171363.
30. Guerin M, Le Goff W, Duchene E, Julia Z, Nguyen T, Thuren T, Shear CL, Chapman MJ, Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler Thromb Vasc Biol 2008 28 148 154. doi: 10.1161/ATVBAHA.107.151688.
31. Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R, Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol 2013 7 414 422. doi: 10.1016/j.jacl.2013.06.007.
32. Morgan JM, de la Llera-Moya M, Capuzzi DM, Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux. J Clin Lipidol 2007 1 614 619. doi: 10.1016/j.jacl.2007.09.003.
33. Rye KA, Barter PJ, Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004 24 421 428. doi: 10.1161/01.ATV.0000104029.74961.f5.
34. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W, Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009 29 1930 1936. doi: 10.1161/ATVBAHA.109.194548.
35. Duong M, Collins HL, Jin W, Zanotti I, Favari E, Rothblat GH, Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol 2006 26 541 547. doi: 10.1161/01.ATV.0000203515.25574.19.
36. Khera AV, Patel PJ, Reilly MP, Rader DJ, The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 2013 62 1909 1910. doi: 10.1016/j.jacc.2013.07.025.
37. Thuahnai ST, Lund-Katz S, Dhanasekaran P, de la Llera-Moya M, Connelly MA, Williams DL, Rothblat GH, Phillips MC, Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Biol Chem 2004 279 12448 12455. doi: 10.1074/jbc.M311718200.
38. Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain MM, Collet X, Cariou B, Costet P, Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol 2013 33 1484 1493. doi: 10.1161/ATVBAHA.112.300263.
39. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML, Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res 2008 49 1195 1201. doi: 10.1194/jlr.M700426-JLR200.
40. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR, Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006 116 1052 1062. doi: 10.1172/JCI27352.
41. Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, Rudel LL, ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res 2005 46 1205 1212. doi: 10.1194/jlr.M500018-JLR200.
42. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS, Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012 59 2058 2064. doi: 10.1016/j.jacc.2012.01.045.
43. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE, Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol 2013 62 1580 1584. doi: 10.1016/j.jacc.2013.07.023.
44. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007 298 309 316. doi: 10.1001/jama.298.3.309.